Literature DB >> 326402

Adriamycin versus adriamycin plus melphalan in advanced ovarian carcinoma.

G M De Palo, M De Lena, G Bonadonna.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 326402

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  5 in total

Review 1.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

2.  Prospective study with HEXA-CAF combination in ovarian carcinoma.

Authors:  G De Palo; R Demicheli; P Valagussa; M De Lena; E Villa
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

3.  Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

Authors: 
Journal:  BMJ       Date:  1991-10-12

4.  The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?

Authors:  David E Cohn; William S Shimp
Journal:  Gynecol Oncol Rep       Date:  2015-06-25

5.  Dose intensity analysis in advanced ovarian cancer patients.

Authors:  V Torri; E L Korn; R Simon
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.